Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article
- PMID: 29148864
- PMCID: PMC5899278
- DOI: 10.1089/jop.2017.0022
Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article
Abstract
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neovascularization (CNV) activity. To assess the persistence/recurrence of lesion activity in patients undergoing treatment for nAMD, an expert panel developed a decision algorithm based on the morphological features of CNV. After evaluating all current retinal imaging techniques, the panel identified optical coherent tomography as the most reliable tool to ascertain lesion activity when funduscopy is not obvious.
Keywords: antivascular endothelial growth factor; choroidal neovascularization; lesion activity; morphologic criteria; neovascular age-related macular degeneration.
Conflict of interest statement
No competing financial interests exist.
Figures

Similar articles
-
The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.Lasers Surg Med. 2016 Sep;48(7):668-77. doi: 10.1002/lsm.22531. Epub 2016 Apr 25. Lasers Surg Med. 2016. PMID: 27111455 Clinical Trial.
-
Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.BioDrugs. 2016 Aug;30(4):353-9. doi: 10.1007/s40259-016-0179-0. BioDrugs. 2016. PMID: 27189458 Clinical Trial.
-
Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.Am J Ophthalmol. 2014 Aug;158(2):337-44. doi: 10.1016/j.ajo.2014.05.007. Epub 2014 May 17. Am J Ophthalmol. 2014. PMID: 24844972
-
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.Curr Drug Targets. 2011 Feb;12(2):149-72. doi: 10.2174/138945011794182746. Curr Drug Targets. 2011. PMID: 20887246 Review.
-
[Treatment of age-related macular degeneration: Expert opinion and therapeutic algorithm].J Fr Ophtalmol. 2015 Sep;38(7):639-45. doi: 10.1016/j.jfo.2015.06.001. Epub 2015 Aug 24. J Fr Ophtalmol. 2015. PMID: 26314897 Review. French.
Cited by
-
Sensitivity and specificity of optical coherence tomography angiography in the diagnosis of active choroidal neovascularization: a systematic review and meta-analysis.Graefes Arch Clin Exp Ophthalmol. 2021 Dec;259(12):3529-3536. doi: 10.1007/s00417-021-05239-4. Epub 2021 Jun 10. Graefes Arch Clin Exp Ophthalmol. 2021. PMID: 34110450
-
Evaluation of Choroidal Structure in Type 1 Macular Neovascularization Using Different Optical Coherence Tomography Analyses: Scale Bar and Binarization.J Clin Med. 2024 Feb 28;13(5):1383. doi: 10.3390/jcm13051383. J Clin Med. 2024. PMID: 38592228 Free PMC article.
-
Optical coherence tomography biomarkers for myopic choroidal neovascularization treated with anti-vascular endothelial growth factor.Kaohsiung J Med Sci. 2023 Jun;39(6):637-643. doi: 10.1002/kjm2.12669. Epub 2023 Mar 14. Kaohsiung J Med Sci. 2023. PMID: 36916244 Free PMC article.
-
Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.J Clin Med. 2024 Jun 12;13(12):3434. doi: 10.3390/jcm13123434. J Clin Med. 2024. PMID: 38929964 Free PMC article.
-
Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration.Sci Rep. 2023 Nov 30;13(1):21128. doi: 10.1038/s41598-023-48190-6. Sci Rep. 2023. PMID: 38036627 Free PMC article.
References
-
- Klein R., Klein B.E., and Cruickshanks K.J. The prevalence of age-related maculopathy by geographic region and ethnicity. Prog. Retin. Eye Res. 18:371–389, 1999 - PubMed
-
- Wong T.Y., Wong T., Chakravarthy U., et al. . The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 115:116–126, 2008 - PubMed
-
- Klaver C.C., Assink J.J., van Leeuwen R., et al. . Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest. Ophthalmol. Vis. Sci. 42:2237–2241, 2001 - PubMed
-
- Piermarocchi S., Segato T., Scopa P., et al. . The prevalence of age-related macular degeneration in Italy (PAMDI) study: report 1. Ophthalmic. Epidemiol. 18:129–136, 2011 - PubMed
-
- Wong W.L., Su X., Li X., et al. . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet. Glob. Health. 2:e106–e116, 2014 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical